The UK’s medicines regulator has issued an important safety update for millions of people using popular weight-loss and diabetes injections, after identifying a very small risk of severe pancreatitis linked to GLP-1 medicines.
In an announcement made on 29 January 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance for healthcare professionals and patients on glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP medicines. These treatments, which include widely used drugs such as Ozempic, Wegovy and Mounjaro, are prescribed for type 2 diabetes, weight management and, in some cases, to reduce cardiovascular risk.
Acute pancreatitis, an inflammation of the pancreas, is already recognised as a rare side effect of GLP-1 medicines. However, the MHRA said that in extremely uncommon cases the condition can become severe, prompting fresh reminders for patients and clinicians to remain alert to early warning signs. These include intense and persistent stomach pain that can spread to the back, often accompanied by nausea or vomiting.
The update comes as the use of GLP-1 medicines has surged across the UK, including among Black, African, Caribbean and other diaspora communities who are disproportionately affected by type 2 diabetes and obesity. Recent research from University College London estimates that around 1.6 million adults in England, Wales and Scotland used GLP-1 drugs for weight loss between early 2024 and early 2025, reflecting their growing role in modern healthcare.
While regulators stress that these medicines remain safe and effective for the vast majority of patients, the MHRA is keen to ensure that people understand both the benefits and the risks. Alison Cave, the agency’s Chief Safety Officer, said patient safety remains the regulator’s top priority and that continuous monitoring allows emerging risks to be identified early.
She emphasised that the likelihood of developing severe pancreatitis is very small, but awareness is crucial. Patients taking GLP-1 medicines are being advised to seek urgent medical attention if they experience symptoms such as severe, ongoing stomach pain, particularly if it radiates to the back or is accompanied by vomiting. Suspected side effects should also be reported through the MHRA’s Yellow Card scheme, which helps regulators track medicine safety across the UK.
Between 2007 and October 2025, the MHRA received 1,296 Yellow Card reports of pancreatitis linked to GLP-1 receptor agonists. Although this figure represents a tiny proportion of overall users, it has helped inform further research into why some individuals may be more vulnerable than others.
As part of this effort, the Yellow Card Biobank, a partnership between the MHRA and Genomics England, is studying whether genetic factors may influence the risk of pancreatitis in people taking GLP-1 medicines. Researchers hope this work will eventually allow doctors to better predict who is most at risk and tailor prescriptions more safely, a development that could particularly benefit diverse communities with different genetic backgrounds.
Health experts continue to stress that patients should not stop taking prescribed medication without medical advice. Instead, they are encouraged to have informed conversations with their GP or specialist, especially if they have a history of pancreatic problems or develop new symptoms.
For diaspora communities following health developments in the UK, the update is a reminder of the importance of staying informed, reporting side effects and engaging proactively with healthcare services. As GLP-1 medicines play an increasingly central role in managing long-term conditions, regulators say transparency and early action remain key to protecting patient health.